Latest period
$31.20B
YoY change
+87.0%
5Y CAGR
+36.3%
Peak year (2025)
$26.54B
Latest annual
$26.54B
Total Equity history chart for Eli Lilly (LLY) from 1985 to 2025
Latest: $26.54B
Total Equity growth chart for Eli Lilly (LLY) from 1985 to 2025
Latest: +87.0%
Total Equity history table for Eli Lilly (LLY) from 1985 to 2025
| 2025 | $26.54B | +87.0% | +$12.34B | ||
| 2024 | $14.19B | +31.8% | +$3.42B | ||
| 2023 | $10.77B | +1.1% | +$122.10M | ||
| 2022 | $10.65B | +18.6% | +$1.67B | ||
| 2021 | $8.98B | +59.2% | +$3.34B | ||
| 2020 | $5.64B | +116.4% | +$3.03B | ||
| 2019 | $2.61B | -73.5% | −$7.22B | ||
| 2018 | $9.83B | -15.2% | −$1.76B | ||
| 2017 | $11.59B | -17.2% | −$2.42B | ||
| 2016 | $14.01B | -3.9% | −$563.60M | ||
| 2015 | $14.57B | -5.2% | −$801.90M | ||
| 2014 | $15.37B | -12.8% | −$2.26B | ||
| 2013 | $17.63B | +19.4% | +$2.87B | ||
| 2012 | $14.77B | +9.0% | +$1.22B | ||
| 2011 | $13.54B | +9.0% | +$1.12B | ||
| 2010 | $12.42B | +30.4% | +$2.90B | ||
| 2009 | $9.52B | +41.4% | +$2.79B | ||
| 2008 | $6.74B | -50.1% | −$6.77B | ||
| 2007 | $13.50B | +23.0% | +$2.52B | ||
| 2006 | $10.98B | +1.7% | +$188.80M | ||
| 2005 | $10.79B | -1.2% | −$128.00M | ||
| 2004 | $10.92B | +11.8% | +$1.16B | ||
| 2003 | $9.76B | +18.0% | +$1.49B | ||
| 2002 | $8.27B | +16.5% | +$1.17B | ||
| 2001 | $7.10B | +17.5% | +$1.06B | ||
| 2000 | $6.05B | +20.6% | +$1.03B | ||
| 1999 | $5.01B | +13.2% | +$583.40M | ||
| 1998 | $4.43B | -4.6% | −$216.00M | ||
| 1997 | $4.65B | -23.8% | −$1.45B | ||
| 1996 | $6.10B | +12.3% | +$667.50M | ||
| 1995 | $5.43B | +1.4% | +$77.00M | ||
| 1994 | $5.36B | +17.2% | +$786.80M | ||
| 1993 | $4.57B | -6.6% | −$323.30M | ||
| 1992 | $4.89B | -1.5% | −$74.00M | ||
| 1991 | $4.97B | +43.2% | +$1.50B | ||
| 1990 | $3.47B | -7.7% | −$289.60M | ||
| 1989 | $3.76B | +16.5% | +$531.80M | ||
| 1988 | $3.23B | +6.0% | +$182.70M | ||
| 1987 | $3.04B | +11.1% | +$303.00M | ||
| 1986 | $2.74B | +14.7% | +$351.90M | ||
| 1985 | $2.39B | — | — |
- 2025$26.54B+87.0%
- 2024$14.19B+31.8%
- 2023$10.77B+1.1%
- 2022$10.65B+18.6%
- 2021$8.98B+59.2%
- 2020$5.64B+116.4%
- 2019$2.61B-73.5%
- 2018$9.83B-15.2%
- 2017$11.59B-17.2%
- 2016$14.01B-3.9%
- 2015$14.57B-5.2%
- 2014$15.37B-12.8%
- 2013$17.63B+19.4%
- 2012$14.77B+9.0%
- 2011$13.54B+9.0%
- 2010$12.42B+30.4%
- 2009$9.52B+41.4%
- 2008$6.74B-50.1%
- 2007$13.50B+23.0%
- 2006$10.98B+1.7%
- 2005$10.79B-1.2%
- 2004$10.92B+11.8%
- 2003$9.76B+18.0%
- 2002$8.27B+16.5%
- 2001$7.10B+17.5%
- 2000$6.05B+20.6%
- 1999$5.01B+13.2%
- 1998$4.43B-4.6%
- 1997$4.65B-23.8%
- 1996$6.10B+12.3%
- 1995$5.43B+1.4%
- 1994$5.36B+17.2%
- 1993$4.57B-6.6%
- 1992$4.89B-1.5%
- 1991$4.97B+43.2%
- 1990$3.47B-7.7%
- 1989$3.76B+16.5%
- 1988$3.23B+6.0%
- 1987$3.04B+11.1%
- 1986$2.74B+14.7%
- 1985$2.39B—
Total Equity values are taken from Eli Lilly's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's latest reported total equity is $31.20B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Eli Lilly (LLY) most recent annual total equity stands at $26.54B (2025) – surged 87.0% year-over-year.
Eli Lilly total equity has grown for 6 consecutive years, with a +36.3% compound annual growth rate over 2020–2025 (5 years).
Across the available history, total equity reached its high of $26.54B in 2025 and its low of $2.39B in 1985.
Eli Lilly Total Equity by Year
Eli Lilly Total Equity 2025: $26.54B
In 2025, Eli Lilly reported total equity of $26.54B, surged 87.0% from 2024. This figure represents the highest annual value in the available history.
Eli Lilly Total Equity 2024: $14.19B
Eli Lilly total equity in 2024 was $14.19B, surged 31.8% from 2023.
Eli Lilly Total Equity 2023: $10.77B
2023's total equity for Eli Lilly came in at $10.77B, edged up 1.1% from 2022.
Eli Lilly Total Equity 2022: $10.65B
Eli Lilly posted total equity of $10.65B in 2022, grew 18.6% from 2021.
Eli Lilly Total Equity 2021: $8.98B
Eli Lilly total equity in 2021 was $8.98B.
See more financial history for Eli Lilly (LLY).
Sector peers by Total Equity
Healthcare peers of Eli Lilly (LLY), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $53.41B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $8.66B
- −$3.27B
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation